Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

…, J Eckman, J Fan, A Fekete, B Firestone…

Index: Shultz, Michael D.; Cao, Xueying; Chen, Christine H.; Cho, Young Shin; Davis, Nicole R.; Eckman, Joe; Fan, Jianmei; Fekete, Alex; Firestone, Brant; Flynn, Julie; Green, Jack; Growney, Joseph D.; Holmqvist, Mats; Hsu, Meier; Jansson, Daniel; Jiang, Lei; Kwon, Paul; Liu, Gang; Lombardo, Franco; Lu, Qiang; Majumdar, Dyuti; Meta, Christopher; Perez, Lawrence; Pu, Minying; Ramsey, Tim; Remiszewski, Stacy; Skolnik, Suzanne; Traebert, Martin; Urban, Laszlo; Uttamsingh, Vinita; Wang, Ping; Whitebread, Steven; Whitehead, Lewis; Yan-Neale, Yan; Yao, Yung-Mae; Zhou, Liping; Atadja, Peter Journal of Medicinal Chemistry, 2011 , vol. 54, # 13 p. 4752 - 4772

Full Text: HTML

Citation Number: 30

Abstract

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG ...